Skip to main content

Table 1 Recommended therapy management after index event

From: Evaluation of therapy management and outcome in Takotsubo syndrome

  Study population n = 72
Therapy recommendation
 ASA 59 (81.9%)
 Clopidogrel 28 (38.8%)
 Prasugrel 2 (2.8%)
 Ticagrelor 4 (5.6%)
 OAC 12 (16.6%)
 LWMH once per day 1 (1.4%)
 Statin 47 (65.3%)
 Beta-blocker 63 (87.5%)
 ACE inhibitor/AT inhibitor 63 (87.5%)
 Mineralocorticoid receptor antagonist 31 (43.1%)
Duration of antithrombotic therapy
 No recommendation 41 (56.9%)
 With recommendation: 29 (40.3%)
 1 month 4 (5.6%)
 3 months 8 (11.1%)
 6 months 6 (8.3%)
 12 months 11 (15.3%)
Reason for OAC
 Atrial fibrillation 10 (13.8%)
 Heart failure 1 (1.4%)
 Deep vein thrombosis 1 (1.4%)
  1. Data is presented as number of patients and percentage
  2. LWMH low weight molecular heparin, OAC oral anticoagulation
  3. Antithrombotic therapy includes antiplatelet mono- or dual therapy or oral anticoagulation